No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ACHV240517C2500
- 2.77
- +0.22+8.63%
15min DelayClose May 15 15:59 ET
2.77High2.70Low
2.70Open2.55Pre Close13 Volume13 Open Interest2.50Strike Price3.57KTurnover914.36%IV3.17%PremiumMay 17, 2024Expiry Date2.71Intrinsic Value100Multiplier1DDays to Expiry0.06Time Value100Contract SizeAmericanOptions Type0.9231Delta0.0411Gamma1.81Leverage Ratio-0.1204Theta0.0001Rho1.67Eff Leverage0.0006Vega
Intraday
- 5D
- 1D
News
Buy Rating Affirmed: Achieve Life Sciences' Promising Path to Cytisinicline NDA and Strong Financial Outlook
Buy Rating Affirmed for Achieve Life Sciences Amid Positive Drug Development Progress and Strong Financial Position
Achieve Life Sciences Is Maintained at Outperform by Oppenheimer
Achieve Life Sciences Is Maintained at Outperform by Oppenheimer
Oppenheimer: Maintain the Achieve Life Sciences (ACHV.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $18.00 to $11.00.
Oppenheimer: Maintain the Achieve Life Sciences (ACHV.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $18.00 to $11.00.
Oppenheimer Maintains Outperform on Achieve Life Sciences, Lowers Price Target to $11
Oppenheimer analyst Francois Brisebois maintains Achieve Life Sciences (NASDAQ:ACHV) with a Outperform and lowers the price target from $18 to $11.
Achieve Life Sciences Inc (ACHV) Reports Q1 2024 Financial Results